[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urinary-urgency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urinary-urgency":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,74,100,128,156],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100640507","essential-oils-for-urinary-symptoms-in-multiple-sclerosis-patients-100640507",false,"NCT07599189","Essential Oils for Urinary Symptoms in Multiple Sclerosis Patients","Efficacy and Safety of Essential Oil Aromatherapy on Neurogenic Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis: A Randomized Single-Blind Placebo-Controlled Clinical Trial.","AROMA-MS","Inclusion Criteria:\n\n* Confirmed diagnosis of Multiple Sclerosis (any form)\n* Documented lower urinary tract symptoms defined by an Overactive Bladder Symptom Score (OABSS) ≥ 3 at screening\n* Age between 18 and 65 years\n* Willing and able to provide written informed consent\n* Capable of performing daily topical self-application of the study oil, or having a caregiver available to assist throughout the study period\n\nExclusion Criteria:\n\n* Active urinary tract infection confirmed by urine culture at screening\n* Pre-existing urological condition unrelated to Multiple Sclerosis (e.g., bladder cancer, benign prostatic hyperplasia, or interstitial cystitis)\n* Known allergy or hypersensitivity to essential oils, apricot kernel oil, lavender, or rosemary\n* Active skin lesions, wounds, or dermatological conditions on the lower abdomen at the intended site of application\n* Pregnancy, breastfeeding, or planning to become pregnant during the study period\n* Significant cognitive impairment preventing understanding of study procedures or completion of questionnaires\n* Current use of an indwelling urinary catheter or practice of intermittent self-catheterization","ALL",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to learn if essential oil aromatherapy works to improve urinary symptoms in adults with multiple sclerosis. It will also learn about the safety of essential oil use in this population.\n\nThe main questions it aims to answer are:\n\n* Does essential oil aromatherapy reduce urinary urgency, frequency, and incontinence episodes in participants with multiple sclerosis?\n* What medical problems do participants have when using essential oil aromatherapy?\n\nResearchers will compare essential oil aromatherapy to a placebo (a look-alike neutral oil with no therapeutic properties) to see if essential oil aromatherapy works to improve urinary symptoms in multiple sclerosis patients.\n\nParticipants will:\n\n* Use essential oil aromatherapy or a placebo oil every day for 6 weeks\n* Complete a urinary symptom scales to record the frequency, urgency, and any leakage episodes each day\n* Fill out quality of life questionnaires at the beginning and end of the study",[26,27,28,29,30],"Multiple Sclerosis (MS)","Neurogenic Bladder Disorder","Urinary Incontinence (UI)","Urinary Urgency","Lower Urinary Tract Symptoms (LUTS)","NOT_YET_RECRUITING","2026-05-16",{"date":34,"type":35},"2026-05-20","ACTUAL",{"date":37,"type":20},"2026-09",{"date":39,"type":20},"2027-03",{"name":41,"class":42},"University of Oran 1","OTHER",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100634483","effectiveness-of-ambulatory-transcutaneous-tibial-nerve-stimulation-for-overactive-bladder-100634483","NCT07540273","Effectiveness of Ambulatory Transcutaneous Tibial Nerve Stimulation for Overactive Bladder","A Single-Center Randomized Controlled Trial Evaluating the Effectiveness of Ambulatory Transcutaneous Tibial Nerve Stimulation Compared to Conventional Protocol in Patients With Overactive Bladder","Inclusion Criteria:\n\n* Adults aged 18 to 65 years\n* Clinical diagnosis of overactive bladder (OAB)\n* Working in an office setting or spending most of the day at home, suitable for using a portable TENS device\n\nExclusion Criteria:\n\n* Pregnancy\n* Cardiac pacemaker\n* Epilepsy\n* Metal implant in the ankle area\n* Open wound or skin disease at the electrode site\n* Active urinary tract infection\n* Neurological disease affecting bladder function\n* Previous surgery for urinary incontinence or OAB\n* Current anticholinergic or beta-3 agonist use for OAB\n* Cognitive impairment preventing proper device use","18 Years","65 Years",{"count":19,"type":20},[23],"The goal of this clinical trial is to learn if using a portable nerve stimulation (TENS) device during daily life works to reduce overactive bladder (OAB) symptoms in adults aged 18 to 65. The main questions it aims to answer are:\n\n* Does using TENS at home during daily activities reduce the number of urgency episodes?\n* Does this approach improve bladder symptoms and quality of life as much as clinic-based treatment?\n\nResearchers will compare two ways of using TENS applied to the ankle area (tibial nerve stimulation):\n\n* Group 1 (Clinic-based): Participants will visit the clinic twice a week for 2 weeks and receive 30-minute TENS sessions.\n* Group 2 (Ambulatory): Participants will use a portable TENS device at home during their daily routine when they feel the urge to urinate, over a 2 week period.\n\nBoth groups will use the same electrical settings (20 Hz frequency, 200 µs pulse width).\n\nParticipants will:\n\n* Complete bladder symptom questionnaires before and after the study\n* Fill in a 3-day voiding diary to track how often they urinate, urgency episodes, and any leakage\n* Answer quality of life questions at the start and at 4 weeks",[57,29],"Overactive Bladder (OAB)",[59,60,61,62,29],"Transcutaneous Tibial Nerve Stimulation","Overactive Bladder","Ambulatory Neuromodulation","Self-Administered Electrical Stimulation","2026-04-17",{"date":65,"type":35},"2026-04-20",{"date":67,"type":20},"2026-04-15",{"date":69,"type":20},"2026-12-15",{"name":71,"class":72},"SEZGIN","OTHER_GOV",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":73},"100429512","btl-emsella-chair-versus-sham-for-the-treatment-of-overactive-bladder-100429512","NCT04873037","BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder","A Single-Blind, Randomized Study of the BTL EmsellaTM Chair Versus Sham for the Treatment of Overactive Bladder","EmsellaOAB","Inclusion Criteria:\n\n1. Able to read, understand, and provide written, dated, informed consent prior to screening, and be likely to comply with study protocol, including independently complete study questionnaires and communicate with study personnel about AEs and other clinically important information.\n2. Women and men ≥ 18 years of age\n3. Self-reported bladder symptoms present ≥ 3 months\n4. Self-reported failed conservative care of behavioral modifications and\u002For oral medications\n5. On a stable dose of antimuscarinics\u002Fbeta-3 agonists for ≥ 4 weeks, and willing to remain on the medication for the duration of the study OR discontinued antimuscarinics\u002Fbeta-3 agonists for ≥ 2 weeks\n6. Ambulatory and able to use a toilet independently, without difficulty\n7. Subject agrees not to start any new treatment for OAB (medication or otherwise) during the treatment and follow-up periods.\n\n   For Females Only:\n8. If of child-bearing age and female, agree to practice approved birth-control methods (oral contraceptives, condom barrier, injection, diaphragm or cervical cap, vaginal contraceptive ring, IUD, implantable contraceptive, surgical sterilization (bilateral tubal ligation), vasectomized partner(s))\n\nExclusion Criteria:\n\n1. Botox® use in bladder or pelvic floor muscles in the past year\n2. Subject weighs greater than 330 pounds\n3. Pulmonary insufficiency, defined as difficulty breathing and fatigue, especially during exercise; chest pain, such as squeezing, pressure of tightness; the sensation of rapid or irregular heartbeat (palpitations); swelling of the legs or feet; dizziness or fainting; and\u002For bluish discoloration of the nails and\u002For lips (cyanosis)\n4. Any condition that causes a lack of normal skin sensation to the pelvis, buttocks, and thighs, at the discretion of the investigator.\n5. Major metal implants such as: metal plates, screws, joint replacements, implanted cardiac pacemakers, drug pumps, neurostimulators, electronic implants, copper intrauterine devices, defibrillators, and metal implants in the pelvic area. Patients with other metal implants will be evaluated by the investigator for inclusion in the study.\n6. Subject has a piercing between the waist and knees and is not willing to remove it before each treatment\n7. Active urethral diverticula\n8. Known vesicoureteral reflux\n9. Currently healing from surgical procedures where muscle contraction may disrupt the healing process\n10. Subject is currently receiving treatment for a malignant tumor that would interfere with study participation. Skin cancers are permitted.\n11. Subject has used the BTL EMSELLA device previously\n12. Subject has urinary incontinence of neurogenic etiology, such as multiple sclerosis, spina bifida, Parkinson's, spinal cord injury, diabetic neuropathy, neurogenic bladder etc.\n13. Current urinary tract infection. If a subject has a confirmed symptomatic UTI at screening, per investigator's clinical judgment, they will be deferred from screening until treatment is completed, and may resume once symptoms have resolved\n14. Current use of neuromodulation therapy, including interstim and PTNS, for bladder symptoms within 3 months of screening visit (if past sacral\u002Fpudendal implant, must be explanted)\n15. Currently participating in an investigational study that may impact study results or previously received an investigational drug or treatment within 30 days of the Screening Visit\n16. Current or history of any physical condition that, in the investigator's opinion, might put the subject at risk or interfere with study results interpretation\n\n    For Females Only:\n17. Pregnant, or planning to become pregnant, at screening or anytime throughout the study period\n\n    * Note: For the sake of preserving scientific integrity, one or more of the eligibility criteria have been left off the list posted while the trial is ongoing. A full list of eligibility criteria will be posted upon completion of the trial.",{"count":83,"type":20},166,[23],"The purpose of this clinical trial is to compare the Emsella Chair therapy to Sham and to determine whether electromagnetic technology is effective in the treatment of overactive bladder (OAB). Currently there are no other studies utilizing the Emsella Chair for the treatment of OAB. Eligible subjects will receive 2 treatments per week for a total of 4 weeks.",[87,60,88,29],"Overactive Bladder Syndrome","Urinary Frequency",[60],"RECRUITING","2025-12-05",{"date":93,"type":35},"2025-12-11",{"date":95,"type":35},"2021-11-22",{"date":97,"type":20},"2028-12",{"name":99,"class":42},"Corewell Health East",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":108,"minAge":109,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":21,"phases":112,"briefSummary":113,"conditions":114,"keywords":117,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":127},"100577357","approve-trial-evaluating-a-prescription-digital-therapeutic-for-treatment-of-oab-in-women-100577357","NCT06797245","APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women","The APPROVE Trial: A Randomized Controlled Trial Evaluating the Efficacy and Safety of a Prescription Digital Therapeutic for Treatment of Overactive Bladder in Women","APPROVE","Inclusion Criteria:\n\n* Women ≥ 22 years old\n* Bothersome OAB symptoms (defined as bother rating ≥ 5 on ICIQ-FLUTS question #3b or #9b)\n* English-speaking\n* Willing to forego other treatment outside of medications for the 8-week trial period\n* Use of at least one mobile App\n\nExclusion Criteria:\n\n* Stress-predominant mixed urinary incontinence (defined as QUID stress score \\> QUID urge score)\n* Voiding dysfunction defined as response ≥ 2 on ICIQ-FLUTS question #7a\n* Bladder pain defined as response ≥ 2 on ICIQ-FLUTS question #4a\n* Use of an OAB medication (anticholinergic or beta-agonist) within the past two weeks\n* Currently using intermittent or indwelling catheter\n* History of bladder\u002Furethral, colon\u002Fanal, or cervical cancer\n* Current or prior use of sacral neuromodulation, tibial stimulation or onabotulinum toxin type A intradetrusor injection\n* Currently taking antibiotics\u002Fdrugs for urinary tract infection\\^\n* Currently undergoing or unwilling to forego pelvic floor physical therapy with a physical therapist or prescription device for the 8-week intervention period\n* Planning surgery for pelvic organ prolapse within 12 months of randomization\n* Pelvic surgery within the past 6 months\n* Planning to undergo pessary fitting °\n\n  * Those on antibiotics for urinary tract infection will be eligible for enrollment 2 weeks after completing antibiotic therapy with subjective resolution of UTI symptoms °Will be eligible after completing pessary fitting\n\nhttps:\u002F\u002Fresearchdata.medstar.net\u002Fredcap\u002Fsurveys\u002F?s=MM7WN7EXACX4PNXJ","FEMALE","22 Years",{"count":111,"type":20},596,[23],"The APPROVE trial is a multi-centered, randomized controlled trial designed to assess differences in symptom improvement, quality of life, bladder symptoms, satisfaction with treatment and continued treatment efficacy in women with overactive bladder (OAB) randomized to a prescription digital therapeutic (PDTx) app called RiSolve compared to standard behavioral education (handouts).",[57,29,115,116,88],"Urinary Urge Incontinence (UUI)","Nocturia",[57],"2025-10-24",{"date":120,"type":35},"2025-10-27",{"date":122,"type":35},"2025-03-17",{"date":124,"type":20},"2028-07",{"name":126,"class":42},"Medstar Health Research Institute",10,{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":108,"minAge":51,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":21,"phases":137,"briefSummary":139,"conditions":140,"keywords":143,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":73},"100569541","phase-4-optimal-intravesical-lidocaine-volume-for-pain-relief-during-office-intra-detrusor-onabotulinum-toxin-a-injections-100569541","NCT06695585","Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections","Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections: a Prospective Randomized Superiority Trial","Inclusion Criteria:\n\n* Adult female, \\>18 years, English-speaking (surveys utilized are not validated in all languages)\n* Able to provide informed consent\n* Indications: Refractory urge urinary incontinence, Refractory urinary urgency and frequency, Neurogenic bladder (without sensory deficit)\n\nExclusion Criteria:\n\n* Untreated urinary tract infection at the time of procedure\n* Contra-indication to Botox\n* Contraindication to intravesical lidocaine\n* Inability to provide informed consent\n* Pregnancy, breast-feeding, intending to become pregnant within 6 months of treatment",{"count":136,"type":20},36,[138],"PHASE4","The purpose of our study is to evaluate the efficacy and safety of different volumes of bladder-numbing medication for pain relief at the time of office bladder Botox injections. This is a randomized prospective, double-blind superiority trial comparing 200 ml 2% lidocaine versus 30 ml 2% lidocaine for office Botox injections.",[60,87,29,88,141,142],"Urge Incontinence","Neurogenic Bladder",[144,145,146],"Bladder Botox","Intravesical lidocaine","office Botox","2024-11-15",{"date":149,"type":35},"2024-11-19",{"date":151,"type":20},"2024-12-01",{"date":153,"type":20},"2025-12-01",{"name":155,"class":42},"University of Louisville",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":108,"minAge":51,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":21,"phases":165,"briefSummary":166,"conditions":167,"keywords":170,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":73},"100553217","optimal-injection-interval-for-intra-detrusor-botulinum-toxin-100553217","NCT06483217","Optimal Injection Interval for Intra-Detrusor Botulinum Toxin","Optimal Injection Interval for Intra-Detrusor Botulinum Toxin: A Randomized Controlled Trial Utilizing a Patient-Centered Approach","Inclusion Criteria:\n\n* diagnosis of overactive bladder, detrusor overactivity, urinary urgency, urinary frequency, nocturnal polyuria, or urge urinary incontinence\n* pursuing treatment with intravesical botulinum toxin injections\n\nExclusion Criteria:\n\n\\- non-OAB diagnosis such as pelvic pain or interstitial cystitis",{"count":164,"type":20},100,[23],"The goal of this clinical trial is to see if patients deciding their own follow up times can increase the effectiveness of botulinum toxin (BTX or \"Botox\") injection for overactive bladder (OAB). The main questions it aims to answer are:\n\n* Does the time between repeat injections differ from the 6-month standard when it is based on patient symptoms alone?\n* Does symptom control or patient satisfaction change when patients control their own follow up times?\n\nParticipants will undergo standard botulinum toxin injection into the bladder for OAB treatment and will then be randomly assigned to follow up either at a standard 6-month interval or whenever they feel their symptoms return.",[60,29,168,169],"Urinary Incontinence","Urge Urinary Incontinence",[171,172,173,174,175,176,177,178,179],"intradetrusor botulinum toxin","intravesical botox","intradetrusor botox","bladder chemodenervation","botox","chemodenervation","overactive bladder","urge urinary incontinence","intravesical botulinum toxin","2024-07-15",{"date":182,"type":35},"2024-07-17",{"date":184,"type":20},"2024-07",{"date":186,"type":20},"2025-10",{"name":188,"class":42},"Louisiana State University Health Sciences Center in New Orleans"]